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Folate receptor α (FRα) autoantibodies (FRAAs) are prevalent in autism spectrum disorder
(ASD). They disrupt the transportation of folate across the blood-brain barrier by binding
to the FRα. Children with ASD and FRAAs have been reported to respond well to
treatment with a form of folate known as folinic acid, suggesting that they may be an
important ASD subgroup to identify and treat. There has been no investigation of whether
they manifest unique behavioral and physiological characteristics. Thus, in this study
we measured both blocking and binding FRAAs, physiological measurements including
indices of redox and methylation metabolism and inflammation as well as serum folate
and B12 concentrations and measurements of development and behavior in 94 children
with ASD. Children positive for the binding FRAA were found to have higher serum B12
levels as compared to those negative for binding FRAAs while children positive for the
blocking FRAA were found to have relatively better redox metabolism and inflammation
markers as compared to those negative for blocking FRAAs. In addition, ASD children
positive for the blocking FRAA demonstrated better communication on the Vineland
Adaptive Behavior Scale, stereotyped behavior on the Aberrant Behavioral Checklist and
mannerisms on the Social Responsiveness Scale. This study suggests that FRAAs are
associated with specific physiological and behavioral characteristics in children with ASD
and provides support for the notion that these biomarkers may be useful for subgrouping
children with ASD, especially with respect to targeted treatments.
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INTRODUCTION
Autism spectrum disorder (ASD) is a devastating neurodevelopmental disorder with life-long
consequences that affects young children during critical times in their development. The Center
for Disease Control estimates that 1 in 68 individuals in the United States (∼1–2%) are affected
by an ASD (Developmental Disabilities Monitoring Network Surveillance Year 2010 Principal
Investigators; Centers for Disease Control and Prevention (CDC), 2014). Despite this alarming
prevalence, the etiology of ASD is still poorly understood with several studies suggesting that both
environmental and genetic components may contribute equally to the etiology of ASD (Hallmayer
et al., 2011; Sandin et al., 2014).
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Recent research has suggested that several physiological
abnormalities such as dysfunctional mitochondrial and
redox metabolism and immune abnormalities, alone, or in
combination, are related to the underlying aberrant biological
processes that results in ASD (Rossignol and Frye, 2012b).
Folate is related to many of the physiological systems found
to be abnormal in ASD (Frye and James, 2014) and has been
shown to be protective against the development of ASD when
supplemented in adequate amounts during or before pregnancy
(Schmidt et al., 2012; Suren et al., 2013). Folate is a water-soluble
B vitamin that is essential for numerous metabolic reactions and
normal neurodevelopment (Greenblatt et al., 1994; Black, 2008).
In some individuals with ASD, the primary mechanism
that transports folate across the blood-brain barrier may be
compromised. The folate receptor alpha (FRα) along with the
energy dependent endocytosis transports folate, attached to the
FRα, from the apical to the basolateral side of the choroid plexus
endothelium against a concentration gradient. Active transport
of folate is necessary because the folate concentration in the
central nervous system is several times higher than the folate
concentration in the blood (Frye et al., 2013b).
A new neurometabolic disorder called cerebral folate
deficiency (CFD) was described about a decade ago. CFD
is characterized by abnormally low folate concentrations in
the cerebrospinal fluid despite normal folate concentration in
the serum (Ramaekers et al., 2002). CFD is associated with
autoantibodies to the FRα which impair its function (Ramaekers
et al., 2005). Serum titers of FRα autoantibodies (FRAAs)
have been correlated with cerebrospinal fluid (CSF) folate
concentrations in independent studies (Ramaekers et al., 2005;
Frye et al., 2013b). Mitochondrial disorders can cause CFD
because of the lack of energy for the active transportation of
folate across the blood-brain barrier (Ramaekers et al., 2007b;
Garcia-Cazorla et al., 2008; Frye and Naviaux, 2011). Early case-
series of children with CFD described many with ASD features
(Ramaekers and Blau, 2004; Ramaekers et al., 2005).
Recently, Frye et al. (2013b) measured blocking and binding
FRAAs in 93 children with ASD using the assay developed by Dr
Quadros (Ramaekers et al., 2005; Molloy et al., 2009). Overall,
60 and 44% were positive for the blocking and binding FRAAs,
respectively. The high prevalence of FRAAs in ASD children
was verified in a study from Belgium which demonstrated
that 47% of children with ASD were positive for the blocking
FRAA as compared to 3.3% of developmentally delayed non-
ASD controls (Ramaekers et al., 2013b). These prevalence rates
for blocking FRAAs are clearly higher than prevalence rates in
healthy populations which vary from 10 to 15% (Frye et al.,
2013b).
The importance of the FRα is related to the targeted
treatment which can bypass the FRα when it is blocked
and/or dysfunctional. Folinic acid can cross the blood-brain
barrier using the reduced folate carrier (RFC) when the FRα
is blocked by FRAAs or non-functional due to mitochondrial
dysfunction and/or genetic mutations. The RFC has a lower
affinity for folate than the FRα, so a high-dose of folinic
acid is required for treatment. Case-reports (Moretti et al.,
2005) and series (Ramaekers et al., 2005, 2007a) have described
neurological, behavioral and cognitive improvements in children
with CFD and ASD with high-dose folinic acid (0.5–2
mg/kg/day), including complete recovery of ASD symptom in
some and substantial improvements in communication in many
(Ramaekers et al., 2005, 2007a).
Frye et al. (2013b) treated 44 children positive for at least
one FRAA with high-dose folinic acid in an open-label fashion.
After 4 months of treatment, significant improvements in
verbal communication, receptive and expressive language and
stereotypical behavior were noted in the treated children as
compared to a wait list control group who were also FRAA
positive. About two-thirds (66%) of treated children showed
some improvement in language, verbal communication and
stereotyped behavior, with one-third (∼33%) demonstrating
moderate or much improvement in these areas.
Although, this promising evidence suggests that FRAAs are
biomarkers that can identify an important subset of children
with ASD who may respond to a specific treatment, an
investigation into whether the subgroup of ASD children with
FRAA have particular characteristics that can distinguish them
from others with ASD, has not been conducted. Thus, in this
study we examine a sample of children with ASD to determine
the correspondence between FRAA status and behavior and
developmental characteristics. Since the folate pathway is closely
connected with methylation and redox regulation pathways
(Frye and James, 2014), markers of glutathione and methylation
metabolism are also examined. Since antibody production can be
associated with immune activation and increases in inflammation
can be associated with redox and methylation abnormalities
(Rose et al., 2012; Rossignol and Frye, 2014), a marker of
inflammation is also examined.
Since there are two different FRAAs, blocking and blinding,
our analysis determines whether the characteristics investigated
are an effect of blocking or binding FRAAs independently of
one another. Since some individuals will have both blocking
and binding FRAAs, a general linear model is used to
investigate these independent effects. This will be the first time
a difference between these two FRAAs has been investigated.
Such information can not only help better identify children with
ASD who are positive for FRAAs but can help us understand the
consequence and significance of each FRAA in ASD.
MATERIALS AND METHODS
The data from the 94 children with ASD were obtained from two
research protocols approved by the Institutional Review Board
at the University of Arkansas for Medical Science (Little Rock,
AR). Written informed consent was obtained from parents of
participants and assent was waived.
A diagnosis of ASD, required for study entry, was defined
by one of the following: (i) a gold-standard diagnostic
instrument such as the Autism Diagnostic Observation Schedule
and/or Autism Diagnostic Interview-Revised (ADI-R); (ii) the
state of Arkansas diagnostic standard, defined as agreement
of a physician, psychologist and speech therapist; and/or
(iii) Diagnostic and Statistical Manual for Mental Disorders
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diagnosis by a physician along with standardized validated
questionnaires and diagnosis confirmation by the Principal
Investigator (REF). Reconfirmation of the diagnosis using the
ADI-R by an independent research reliable rater was requested
for a portion of participants to confirm that the criteria used
for including the participants was equivalent to other high-
quality studies. Excluded from the study were children on
antipsychotic medications as well as children with well-defined
genetic syndromes.
Folate Autoantibody Assay
About 1 ml of serum was analyzed at the State University of
New York, Downstate (Brooklyn, NY) for blocking and binding
FRAAs using the assay previously described (Ramaekers et al.,
2005; Molloy et al., 2009). Blocking FRAAs are expressed as
pmoles of folic acid blocked from binding to FRα perml of serum,
and binding FRAAs are expressed as pmoles of IgG antibody per
ml of serum.
Redox, Methylation, Immune and Vitamin
Biomarkers
Redox and methylation potential was measured by the
total and free reduced-to-oxidized glutathione redox ratio
(tGSH/GSSG and fGSH/GSSG) and the S-adenosylmethionine
to S-adenosylhomocysteine ratio (SAM/SAH), respectively.
3-Chlorotyrosine (CT), a measure of myeloperoxidase activity,
was used as a marker of immune system activation. Fasting blood
(4 ml) was collected into an EDTA-Vacutainer tube, chilled on
ice and centrifuged at 1500 × g for 15 min at 4◦C. Plasma was
stored at −80◦C and analyzed by HPLC with electrochemical
detection as previously described (Melnyk et al., 1999) within 2
weeks of collection. Total plasma folate and vitamin B12 were
measured using MP Diagnostics SimulTRAC-SNB Radioassay
Kit (Cat# 06B264806).
Cognitive and Behavioral Assessments
The Preschool Language Scale-4 (PLS) and two versions of the
Clinical Evaluations of Language Fundamentals (CELF) were
used to assess language ability. The CELF is one of the only
standardized, well-validated language assessment instruments
that spans the age range of most participants (using both
CELF-preschool-2 and CELF-4; Semel et al., 2003; Wiig et al.,
2004). It assesses a wide range of language skills that are only
partially measured by other language tests, including high-level
language skills that are abnormal in individuals with ASD, such
as language pragmatics (Condouris et al., 2003) and has been
used in several studies focusing on core language deficits in
ASD (Verly et al., 2014; Edgar et al., 2015). The PLS is also
a standardized, well-validated language assessment instrument
that can measure subtle changes in language in children with
poor language abilities (Zimmerman et al., 2002; Volden et al.,
2011). Both instruments provide a standardized core language
score which was used as the index of language ability. For each
participant the most ability appropriate instrument was used in
order to prevent floor and ceiling effects.
Adaptive behavior was assessed using the Vineland Adaptive
Behavior Scales, 2nd Edition, Interview Edition, Survey Form
(VABS), an instrument that has demonstrated good reliability
and validity (Sparrow et al., 2005). Standardized scores for
summary scales were examined: communication, daily living
skills, social skills, motor skills and adaptive behavior composite.
The Aberrant Behavior Checklist (ABC) was designed to
measure disruptive behaviors in individuals with developmental
disabilities (Aman et al., 1985). The ABC has been shown to have
convergent and divergent validity in ASD (Kaat et al., 2014) and
has been used in multiple autism clinical trials (Frye et al., 2015).
The Social Responsiveness Scale (SRS) measures the severity
of social skill deficits (Constantino, 2002). It has been validated
and shown to be reliable and to have good correspondence to the
gold-standard ADI-R, while being more time efficient and cost
effective (Murray et al., 2011).
Statistical Analysis
The “glm” procedure of SAS 9.1 (SAS Institute Inc., Cary,
NC) was used with a two-tailed alpha of 0.05. FRAA status
was dichotomized into positive or negative for both blocking
and/or binding FRAAs. These variables were entered into a
general linear model to determine if differences in the dependent
variable were related to blocking and/or binding FRAA status.
In this sense, the analysis examined the independent effects of
blocking and bindings FRAAs on the dependent variable while
controlling for the effect of each FRAA. Because of the limited
sample size, the interaction of the two FRAAs was not examined.
Planned orthogonal contrasts were used to determine whether
the blocking and binding FRAAs demonstrated significant
differences in the dependent variable. Since ASD symptoms are
often associated with developmental level, the VABS Adaptive
Behavior Composite was used as a covariate in the analysis that
examined behavior and developmental indices.
RESULTS
Participants
Basic participant characteristics are outlined in Table 1 stratified
across FRAA status. The average age and gender did not differ
across the FRAA groups. Race and ethnicity was not different
across FRAA groups. Overall, 84% were Caucasian, 7% African
American, 5% Asian and 3% mixed race and 95% were non-
Hispanic.
Participants were recruited from our research registry (35%),
autism clinic (27%), word-of-mouth (15%), physician referrals
(13%), and community advertisement and social media (11%).
All participants evaluated by an independent research reliable
rater exceeded the threshold for the autism diagnosis.
Overall, immune and neurological abnormalities did not
differ across FRAA status. Of the children with immune
disorders, 79% had recurrent infections, 35% were diagnosed
with immune disorder not otherwise specified, 32% had eczema,
21% had Pediatric Acute-onset Neuropsychiatric Syndrome,
11% had hypogammaglobulinemia and 5% had complement
deficiency. Of the children with neurological abnormalities,
42% had epilepsy, 27% had migraines, 23% had abnormal
electroencephalograms without seizures, 20% had visual
problems, 15% had macrocephaly, 8% had Chiari malformation,
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TABLE 1 | Demographic and clinical characteristics by folate receptor alpha autoantibody groups.
Variable FRAA Negative (n = 40) FRAA Blocking Positive (n = 16) FRAA Binding Positive (n = 48)
Age, years months 7 years 0 months (3 years 4 months) 6 years 5 months (3 years 0 months) 7 years 4 months (3 years 2 months)
Males, N (%) 34 (85%) 15 (94%) 39 (81%)
Vineland adaptive behavior composite, 64.9 (11.7) 66.7 (10.8) 63.2 (10.4)
Only blocking autoantibody positive, N (%) 6 (38%)
Only binding autoantibody positive, N (%) 38 (79%)
Both folate autoantibodies positive, N (%) 10 (63%) 10 (21%)
Blocking titer (pmol/ml), 0.52 (0.36) 0.54 (0.44)
Binding titer (pmol/ml), 1.03 (0.81) 0.85 (0.66)
Glutathione redox ratio, total 30.72 (1.09) 29.67 (1.07) 34.92 (2.06)
Glutathione redox ratio, free 9.06 (1.83) 9.82 (1.82) 8.75 (1.62)
Methylation SAM/SAH Ratio 2.65 (0.48) 2.67 (0.42) 2.60 (0.46)
3-Chlorotyrosine 37.7 (7.6) 33.4 (6.6) 37.1 (7.7)
Folate (ng/ml) [Normal 5-21], 17.7 (4.3) 18.9 (5.3) 18.0 (4.1)
B12 (pg/ml) [Normal 200-900], 828.3 (451.3) 1426.0 (1589.8) 1383.0 (1495.4)
LANGUAGE TESTING, N (%)
Preschool language scales 12 (30%) 4 (25%) 17 (35%)
Clinical evaluation of language fundamentals 2 14 (35%) 6 (38%) 10 (21%)
Clinical evaluation of language fundamentals 4 13 (33%) 6 (38%) 21 (44%)
DIAGNOSTIC DOCUMENTATION, N(%)
Autism diagnostic observation schedule 20 (50%) 8 (50%) 22 (46%)
3 Practitioner agreement 30 (75%) 10 (63%) 31 (65%)
Single practitioner with standardized
questionnaires
5 (13%) 5 (31%) 12 (25%)
AUTISM DIAGNOSTIC INTERVIEW-REVISED
Participated in confirmation testing, N(%) 27 (68%) 11 (69%) 37 (77%)
Social interaction score, 21.41 (5.44) 22.18 (4.40) 22.76 (4.96)
Communication score: verbal, 16.64 (4.40) 18.88 (1.46) 19.43 (3.89)
Communication score: non-verbal, 12.69 (2.36) 12.33 (2.08) 13.07 (1.59)
Restricted and repetitive play score, 5.85 (1.83) 5.82 (2.71) 5.84 (2.39)
Summary score, 4.41 (0.93) 4.64 (0.50) 4.41 (0.93)
MEDICATIONS (CONCURRENT TREATMENTS), N (%)
Melatonin 17 (43%) 1 (6%) 10 (21%)
Allergy/Asthma medications 13 (33%) 4 (25%) 10 (21%)
Gastrointestinal medications 15 (38%) 2 (13%) 9 (19%)
Alpha-adrenergic agonists 7 (18%) 1 (6%) 10 (21%)
Stimulant 6 (15%) 0 (0%) 8 (17%)
Antiepileptic medication 4 (10%) 0 (0%) 6 (13%)
Antimicrobial medications 5 (13%) 1 (6%) 4 (8%)
Selective serotonin reuptake inhibitors 0 (0%) 1 (6%) 6 (13%)
Other psychotropic medications 4 (10%) 0 (0%) 2 (4%)
Immunomodulatory medications 2 (5%) 1 (6%) 2 (4%)
Antipsychotic 2 (5%) 0 (0%) 0 (0%)
Beta blocker 1 (3%) 0 (0%) 0 (0%)
SUPPLEMENTS (CONCURRENT TREATMENTS), N (%)
Multivitamin 13 (33%) 6 (38%) 12 (25%)
Minerals 8 (20%) 3 (19%) 11 (23%)
Fatty acids 7 (18%) 4 (25%) 10 (21%)
Folate 8 (20%) 0 (0%) 7 (15%)
Vitamin B-12 2 (5%) 2 (13%) 12 (25%)
Carnitine 6 (15%) 3 (19%) 7 (15%)
Other antioxidants 4 (10%) 1 (6%) 8 (17%)
Other vitamins 7 (18%) 1 (6%) 5 (10%)
(Continued)
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TABLE 1 | Continued
Variable FRAA Negative (n = 40) FRAA Blocking Positive (n = 16) FRAA Binding Positive (n = 48)
Other B vitamins 3 (8%) 3 (19%) 8 (17%)
CoEnzyme Q10 4 (10%) 1 (6%) 5 (10%)
Other supplements 1 (3%) 0 (0%) 3 (6%)
Amino acids 1 (3%) 1 (6%) 2 (4%)
Thyroid supplements 1 (3%) 0 (0%) 1 (2%)
COMORBID MEDICAL CONDITIONS, N (%)
Allergic disorders 18 (45%) 6 (38%) 19 (40%)
Gastrointestinal disorders 18 (45%) 6 (38%) 17 (35%)
Neurological disorders 9 (23%) 5 (31%) 15 (31%)
Copy number variants 7 (18%) 4 (25%) 14 (29%)
Psychiatric disorders 5 (13%) 3 (19%) 14 (29%)
Immune abnormality 8 (20%) 1 (6%) 10 (21%)
Mean values with standard deviation in parenthesis.
8% had non-specific magnetic resonance imaging abnormalities
of the brain, and 4% had microcephaly.
Folate Receptor Alpha Autoantibodies
Fifty seven percent of the participants were positive for either
the blocking or binding FRAAs, with 17% positive for blocking
FRAA and 51% positive for the binding FRAA; 11%were positive
for both FRAAs. There was no significant difference in age across
participants who were FRAA blocking positive vs. negative or
FRAA binding positive vs. negative.
Folate and B12
B12 [F(1, 92) = 4.35, p = 0.03], but not folate, was significantly
higher in the binding FRAA positive participants as compared to
binding FRAA negative participants (See Figure 1). Participants
positive for the blocking FRAA were not, as a group, significantly
different than those negative for the blocking FRAA with respect
to B12 or folate. Neither, B12 nor folate was significantly different
in those positive for blocking FRAAs vs. those positive for the
binding FRAAs.
Redox, Methylation and Inflammation
Biomarkers
As depicted in Figure 2, total and free GSH/GSSG was
significantly higher in participants positive for the blocking
FRAA as compared to those participants negative for the
blocking FRAA [F(1, 92) = 9.52, p= 0.003 and F(1, 92) = 5.35, p=
0.02, respectively]. Total and free GSH/GSSG were significantly
higher in participants positive for blocking FRAAs as compared
to those positive for binding FRAAs [F(1, 92) = 9.06, p = 0.003
and F(1, 92) = 6.76, p= 0.01, respectively].
CT was significantly lower in participants positive for the
blocking FRAA as compared to those negative for the blocking
FRAA [F(1, 92) = 4.83, p = 0.03] but CT was not significantly
different between those positive for blocking FRAA vs those
positive for binding FRAAs.
Since supplemental B12 can improve the GSH/GSSG ratio in
clinical studies, we reanalyzed the difference in GSH/GSSG ratio
across groups with B12 as a covariate but the results did not
changed, indicating that the difference in GSH/GSSG ratio across
groups was not due to differences in serum B12 concentrations.
The SAM/SAH methylation ratio was not significantly
different between blocking FRAA positive and negative groups.
Additionally, participants positive for the binding FRAA were
not, as a group, significantly different than those negative for
the binding FRAA with respect to GSH/GSSG or SAH/SAH ratio
or CT.
Behavior and Cognition
The VABS Adaptive Behavior Composite was not significantly
different in those positive for the blocking FRAA vs. those
negative for the blocking FRAA or those positive for the binding
FRAA vs. those negative for the binding FRAA, suggesting that
any behavioral differences found across FRAA status were not
due to developmental level.
As depicted in Figure 3, VABS Communication [F(1, 86) =
5.95, p = 0.02], ABC Stereotyped Behavior [F(1, 84) = 5.30, p =
0.02] and SRS Mannerisms [F(1, 82) = 5.19, p = 0.03] were
significantly better in participants positive for blocking FRAA as
compared to those negative for blocking FRAA. Total SRS Score
was significantly better in those positive for the blocking FRAA as
compared to those positive for the binding FRAA [F(1, 82) = 4.04,
p = 0.05]. None of the behavioral or developmental measures
were different across those positive vs. negative for the binding
FRAA.
DISCUSSION
FRAAs (both blocking and binding) are believed to have
pathologic consequences in ASD because of their role in blocking
the transport of folate into the brain by interfering with FRα
function and reducing folate availability in the brain (Frye et al.,
2013b). Several studies have documented that individuals with
FRAAs, including those with CFD, have ASD characteristics
(Ramaekers and Blau, 2004; Ramaekers et al., 2005) and the
prevalence of FRAAs appears to be high in individuals with
ASD (Frye et al., 2013b; Ramaekers et al., 2013b). However, until
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FIGURE 1 | (A) Children with Autism Spectrum Disorder who are positive for the binding Folate Receptor Alpha Autoantibody have higher serum B12 concentrations
than children negative for the binding Folate Receptor Alpha Autoantibody; (B) Serum Folate concentration does not differ across Folate Receptor Alpha Autoantibody
status in children with Autism Spectrum Disorder.
FIGURE 2 | Children with Autism Spectrum Disorder who are positive for the blocking Folate Receptor Alpha Autoantibody have more favorable total
and free glutathione redox ratios (A,B) and marker of inflammation (C) as compared to those negative for the blocking FRAA. (D) Methylation metabolism
was not different across Folate Receptor Alpha Autoantibody status.
this study no one has examined whether individuals with ASD
who are FRAA positive have behavioral, developmental and/or
physiological characteristics that are distinct from individuals
with ASD who are negative for FRAAs.
In this study we found that individuals with ASD who were
positive for the blocking FRAA demonstrated behavioral and
physiological differences as compared to those negative for the
blocking FRAA and as compared to those positive for the binding
FRAA. Interestingly this subset of children appears to have better
physiological and behavioral profiles, although their behavioral
scores are well within the range for children with ASD. There
is evidence that children positive for the FRAAs respond to
folinic acid therapy, suggesting that these children are a subset of
children with ASD that may be particularly responsive to therapy
that addresses physiological abnormalities. The fact that children
with FRAAs, at least blocking FRAAs, may have less severe ASD
symptoms, suggests that these children may be a group to target
early as they may be very likely to substantially improve their
ASD symptoms and attain optimal outcomes with treatment.
This may explain several reports of children with CFD recovering
from ASD symptoms with high-dose folinic acid therapy—since
they may have started out with milder ASD symptoms it may
have been easier for them to recover.
Interestingly, ASD children with the blocking FRAA appear
to have a more favorable redox and inflammation profile with
relatively better glutathione and CT indices than FRAA blocking
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negative children. A group of children with ASD and relatively
unfavorable redox profiles have been described as having a
distinct metabolic endophenotype in previous studies (James
et al., 2006). It would appear that the group of ASD children
with blocking FRAAs may be a complimentary metabolic
endophenotype to the group with unfavorable redox metabolism
that may have abnormalities specific to folate metabolism rather
than redox metabolism. Importantly, this study demonstrates
how multiple biomarkers can be used to differentiate subgroups
of children with ASD who could potentially respond to different
and/or synergistic treatments.
Children with ASD who are positive for the binding FRAA
did not appear to have significant differences in behavioral,
developmental or physiological measures when compared to
children with ASD who were negative for the binding FRAA
but the group did demonstrate significantly higher serum B12
concentrations. This may suggest that the binding FRAAs
may interfere with cellular B12 uptake, resulting in a higher
concentration of B12 in the blood. Indeed, polymorphisms in the
B12 binding protein have been linked to an increased risk of ASD
(James et al., 2006). Thus, the binding FRAAs may yet be another
mechanism for interfering with B12 metabolism, resulting in
methylation and glutathione abnormalities. Abnormalities in B12
metabolism, especially interference with B12 uptake into the cell,
could result in the glutathione abnormalities seen in participants
with the binding FRAAs. As B12 supplementation can correct
glutathione metabolism abnormalities ASD (James et al., 2009)
and improve adaptive behavior (Frye et al., 2013a) in children
with ASD, it is very possible that a deficit in the cellular uptake of
B12, either through a polymorphism in the B12 binding protein
or binding FRAA interfering with B12 transport, could result in
abnormal glutathione metabolism. Although, we used B12 as a
covariate in the analysis of glutathione differences across groups,
the covariate would only have been significant if it represented
higher levels of intracellular B12. If indeed the higher B12 levels
represent a failure of B12 entering the cell, then the covariate
would have no relation to glutathione levels (or may have had the
opposite predicted relationship). Thus, this is another indication
that the elevated B12 levels associated with the binding FRAA
do not represent intracellular levels and may be a reflection of
a lack of cellular B12 uptake. If this is the case, the binding
FRAA may interfere with both folate and B12 transportation,
resulting in amore severe phenotype. Indeed, individuals positive
for the binding FRAA appear to have worse social skills (as
measured by the SRS) than children positive for the blocking
FRAA.
Because of the limited sample size wemight not have been able
to detect small differences in physiology and behavior between
the groups. Larger sample sizes could be helpful in detecting
more subtle physiological and behavioral differences between
groups. Perhaps an interesting study would be to measure the
variation in FRAA titers within individuals. Titers tend to vary
over short intervals of time (Ramaekers et al., 2013a), but this
study only characterized the participants as FRAA positive or
negative. It may be very useful to monitor changes in both FRAA
titers and behavior within an individual over time as a more
sensitive measure of the relationship between FRAAs titers and
behavior, as examining intra-subject variation can control for the
variation in physiology between individuals. Indeed, one study
has demonstrated that the close relationship between aggression
and blocking FRAA titers over a 6 week period in a 8 year old
girl with ASD (Ramaekers et al., 2007a). Although, this study
did not find any relationship between aggressive behavior and
FRAA status, this may have been due to the large number of
factors that can result in aggressive behavior within an individual
with ASD (Matson and Jang, 2014). Thus, intra-subject studies
may be most sensitive, especially if considering correlating FRAA
titers.
It is important to appreciate that FRAAs could also work in
concert with the defects in folate metabolism that have been
associated with ASD, including polymorphisms in dihydrofolate
reductase (Adams et al., 2007), the reduced folate carrier (James
et al., 2006) and methylenetetrahydrofolate reductase (Frustaci
et al., 2012), and mitochondrial dysfunction which appears to
be rather common in children with ASD (Frye and Rossignol,
2011; Rossignol and Frye, 2012a). In addition, emerging evidence
suggests that the enteric microbiome also has an important role
for regulating the bioavailability of vitamins such as folate and
B12 (Frye et al., 2015). Thus, a study which comprehensively
assesses multiple folate pathway abnormalities in relationship to
ASD behavior could be very insightful.
This study has helped define the importance of FRAAs in
ASD and the effect of the FRAAs on physiology and behavior.
It appears that blocking and binding FRAAs are associated
with slightly different physiological and behavioral effects in
children with ASD. Further, research will help better define their
physiological roles and significance. Studying clinical subgroups
in other disorders associated with FRAAs such as schizophrenia
(Ramaekers et al., 2014) and subfertility (Berrocal-Zaragoza
et al., 2009) may also yield important information. Ultimately,
this information may be important to determining optimal
treatments for certain children with ASD.
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